Last reviewed · How we verify
Anaprazole Sodium enteric-coated tablet
Anaprazole Sodium is an enteric-coated tablet marketed by Sihuan Pharmaceutical Holdings Group Ltd., with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging the protection of its key patent. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Anaprazole Sodium enteric-coated tablet |
|---|---|
| Sponsor | Sihuan Pharmaceutical Holdings Group Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations (PHASE4)
- Drug-drug Interaction Study of Rifampin and Anaprazole Sodium (PHASE4)
- A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis (PHASE2)
- A Multiple Ascending High Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects (PHASE1)
- A Single Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects (PHASE1)
- A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects (PHASE1)
- Pharmacokinetic Interactions of Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: